PMC:7652766 / 25118-25472 JSONTXT

{"project":"LitCovid-PD-HP","denotations":[{"id":"T19","span":{"begin":78,"end":90},"obj":"Phenotype"}],"attributes":[{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"form of the disease (94–96).\nThe risk of applying medication commonly used in hypertension treatments to COVID-19 patients (97, 98) has raised different hypotheses over the issue of invoking a higher expression of ACE2 (99–101). A systematic review assessing the clinical outcomes for SARS-CoV-2-infected individuals regarding treatment using angiotensin"}

{"project":"LitCovid-sentences","denotations":[{"id":"T130","span":{"begin":29,"end":228},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"form of the disease (94–96).\nThe risk of applying medication commonly used in hypertension treatments to COVID-19 patients (97, 98) has raised different hypotheses over the issue of invoking a higher expression of ACE2 (99–101). A systematic review assessing the clinical outcomes for SARS-CoV-2-infected individuals regarding treatment using angiotensin"}

{"project":"LitCovid-PubTator","denotations":[{"id":"960","span":{"begin":214,"end":218},"obj":"Gene"},{"id":"963","span":{"begin":102,"end":104},"obj":"Gene"},{"id":"964","span":{"begin":114,"end":122},"obj":"Species"},{"id":"966","span":{"begin":229,"end":230},"obj":"Gene"},{"id":"967","span":{"begin":191,"end":192},"obj":"Gene"},{"id":"968","span":{"begin":78,"end":90},"obj":"Disease"},{"id":"969","span":{"begin":105,"end":113},"obj":"Disease"},{"id":"970","span":{"begin":285,"end":304},"obj":"Disease"}],"attributes":[{"id":"A960","pred":"tao:has_database_id","subj":"960","obj":"Gene:59272"},{"id":"A963","pred":"tao:has_database_id","subj":"963","obj":"Gene:6999"},{"id":"A964","pred":"tao:has_database_id","subj":"964","obj":"Tax:9606"},{"id":"A966","pred":"tao:has_database_id","subj":"966","obj":"Gene:351"},{"id":"A967","pred":"tao:has_database_id","subj":"967","obj":"Gene:351"},{"id":"A968","pred":"tao:has_database_id","subj":"968","obj":"MESH:D006973"},{"id":"A969","pred":"tao:has_database_id","subj":"969","obj":"MESH:C000657245"},{"id":"A970","pred":"tao:has_database_id","subj":"970","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"form of the disease (94–96).\nThe risk of applying medication commonly used in hypertension treatments to COVID-19 patients (97, 98) has raised different hypotheses over the issue of invoking a higher expression of ACE2 (99–101). A systematic review assessing the clinical outcomes for SARS-CoV-2-infected individuals regarding treatment using angiotensin"}